Fig. 3.

Human monoclonal anti-α3(IV)-PGE₂ conjugates reduce the severity of established nephritis. A and C: normal mouse. B and E: nephrotoxic nephritis (NTN) mice. C and F: NTN mice treated with F1.1-PGE₂ conjugates. Shown is histology (H&E) from day 7 kidneys (A–C) for NTS mice with severe glomerulonephritis and tubulointerstitial injury. Mice that received the F1.1-PGE₂ conjugates had minimal evidence of nephritis. Quantification of H&E images by scoring supported this conclusion (G). The beneficial effect was associated with restoration of synaptopodin expression, as shown (D–F): normal glomeruli (D), NTN mice (E), and NTS/F1.1-PGE₂ (F). Integrated density for synaptopodin images was quantified by using Image J software (H). The quantitative results are shown from 1 representative experiment with 5 mice/group, and they were reproducible. *P < 0.05. **P < 0.01.